Changes of central benzodiazepine receptor density in the course of anticonvulsant treatment in temporal lobe epilepsy.
The first investigation of the central-type benzodiazepine (BZ) receptor density before and following 2 months successful treatment with carbamazepine (CBZ) in a patient with temporal lobe epilepsy (TLE) using 123I-labelled Iomazenil (a specific lipophile central BZ receptor compound) and single photon emission tomography (SPET) is reported. First, a focal slowing of the EEG in the left temporal area was noted and a corresponding reduction of the central BZ density of the left temporal lobe was found. After 2 months of treatment the patient was symptom-free, and a normal BZ receptor density and no pathological EEG signs were found. The increase in central BZ receptor binding sites might be related to the anticonvulsant effects of CBZ mediated by the so-called peripheral BZ receptor sites.
Staedt
J
J
Department of Psychiatry, Georg August University, Goettingen, Germany.
Stoppe
G
G
Kögler
A
A
Steinhoff
B J
BJ
D000328:Adult; D001931:Brain Mapping; D002220:Carbamazepine / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004833:Epilepsy, Temporal Lobe / Q000000981:diagnostic imaging / Q000188:drug therapy*; D005260:Female; D005442:Flumazenil / Q000031:analogs & derivatives; D006801:Humans; D007091:Image Processing, Computer-Assisted; D011869:Radioligand Assay; D011963:Receptors, GABA-A / Q000187:drug effects* / Q000502:physiology; D013702:Temporal Lobe / Q000000981:diagnostic imaging / Q000187:drug effects*; D015899:Tomography, Emission-Computed, Single-Photon
D011963:Receptors, GABA-A; D002220:Carbamazepine; D005442:Flumazenil; C063038:iomazenil